Bleeding and Thrombosis in Chronic Uremia

Nephron

Volumn 75, Issue 2, 1997, Pages 125-139

  Sagripanti, Andrea ^a   Barsotti, Giuliano ^b  

^a Transplant and Advances in Medicine   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLEEDING; PRIORITY JOURNAL; REVIEW; THROMBOSIS; UREMIA;

EID: 0031048628     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000189522     Document Type: Article

References (172)

1. Morgagni GB: Opera Omnia, 1764.
2. Lewis J. Zuckcr M. Ferguson J: Bleeding tendency in uremia. Blood 1957:11:1073-1076.
3. Castaldi PA, Sidney MB: The bleeding disorder of uraemia. Lancet 1966:ii:66-69.
4. Rabiner SF: Uremic bleeding. Prog Hcmost Thromb 1972:1:233-250.
5. Andrassy K. Ritz E: Uremia as a cause of bleeding. Am J Nephrol 1985:5:313-319.
6. Remuzzi G: Bleeding in renal failure. Lancet 1988;i: 1205-1208.
7. Margolis DM, Saylor JL. Geisse G, DeSchrvver-Keeskemeti K. Harter HR. Zuckerman GR: Upper gastrointestinal disease in chronic renal failure. A prospective evaluation. Arch Intern Med 1978:138:1214-1217.
8. Boyle JM. Johnston B: Acute upper gastrointestinal hemorrhage in patients with chronic renal disease. Am J Med 1983;75:409-412.
9. Zuckerman GR. Cornette GL. C'lousc RE. Harter HR: Upper gastrointestinal bleeding in patients with chronic renal failure. Ann Intern Med 1985;102:588-592.
10. Symons HS, Wrong OM: Uremic pericarditis with cardiac tamponade: A report of four cases. BrMedJ 1964;i:605-606.
11. Berger HW. Rammohan G, Neff MS. Buhain WJ: Uremic pleural effusion. A study in 14 patients on chronic dialysis. Ann Intern Med 1975:82:362-364.
12. Bechar M. Lakkc JP. van der Hem GK, et al: Subdural hematoma during long-term hemodialysis. Arch Neurol 1972:26:513-516.
13. Lindner A. Charra B. Sherrard DJ. Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974:290:697-702.
14. Brunner FB. Brynger H. Broyer M. Challan S. Dykes SR: Registry report. Survival on renal replacement therapy: Data from the EDTA Registry. Nephrol Dial Transplant 1988:2:109-122.
15. Degoulet P. Legrain M. Reach I. et al: Mortality risk factors in patients treated by chronic hemodialysis. Report of the 'Diaphane' Collaborative Study. Nephron 1982:31:103-110.
16. Bradley JR, Evans DB, C'alnc RY: Long-term survival in haemodialysis patients. Lancet 1987;i:295-296.
17. Gokal R. Jakubowsky C. King J. et al: Outcome in patients on continuous ambulatory peritoneal dialysis and haemodialysis: 4-vear analysis of a prospective multicentre study, Lancet 1987; ii:1105-1109.
18. Goldberg M. Hoffman GC: Massive hemorrhage from rectal ulcers in chronic renal failure. N Y State J Med 1984:70:2022-2025.
19. Diaz-Buxo JA, Donadio JV In Complications of percutaneous renal biopsy: An analysis of 1,000consecutive biopsies. Clin Nephrol 1975: 4:223-227.
20. Kjellstrand M. Merino CE, Maucr SM. et al: Complications of percutaneous femoral vein catheterization for hemodialysis. Clin Nephrol 1975:4:37-40.
21. Larsson SO. Hcdner U, Nilsson IM: On coagulation and fibrinolysis in uremic patients on maintenance hemodialysis. Acta Med Scand 1971;189:453-462.
22. Panicucci F, Sagripanti A, Pinori E, Vispi M. Lecchini L. Barsotti G. Giovannetti S: Comprehensive study of haemostasis in chronic uraemia. Nephron 1983:33:5-8.
23. Steirer RW. Coggins C. Carvalho ACA: Bleeding t:mc in uremia: A useful test to assess clinical bleeding. Am J Hcmatol 1979:7:107-117.
24. Livio M. Marchesi D, Remuzzi G. Gotti E, Mecca G, de Gaetano G: Uraemic bleeding: Role of anaemia and beneficial effect of red cell transfusions. Lancet 1982:ii: 1013-1015.
25. Moia M, Vizzotto L. Cattaneo M. Mannucci PM. Casati S. Ponticelli C: Improvement in the haemostatic defect on uraemia after treatment with recombinant human erythropoietin. Lancet 1987:ii: 1227-1229.
26. Sagrpanti A. Casalino F. Baicchi U. Barsotti G. Morclli E. Giovannetti S: Effectiveness of a polypeptide fraction from factor VIII on the bleeding tendency of uremic patients. Schweiz Med Wochenschr 1991:121 (suppl 43): 127.
27. Vicncr A. Aviram M. Better OS, Brook JG: Enhanced in vitro platelet aggregation in hemodialysis patients. Nephron 1986:43:139-143.
28. Nakamura Y. Masui N. Nakagawa S: Evaluation of the platelet function of chronically uremic patients on regular dialysis treatment by the platelet sensitivity test. J Jpn Soc Dial Ther 1989:22:1341-1345.
29. George CRP. Slichter SJ. Quadracci LJ. Striker GE, Harkcr LA: A kinetic evaluation of hemostasis in renal disease. N Engl J Med 1974:291: 1111-1115.
30. Guzzo J, Niewiarowski S. Musial J. Basil C. Grossman RA. Koneti R. Berman I. Dieter P: Secreted platelet proteins with antiheparin and mitogenic activities in chronic renal failure. J Lab Clin Med 1980:96:102-113.
31. Green D. Santhanam S, Krumlovsky FA. Sel Greco F: Elevated beta-lhromboglobulin in patients with chronic renal failure: Effects of hemodialysis. J Lab Clin Med 1980:95:679-685.
32. Adler AJ, Lundin AP. Friedman EA. et al: Effect of hemodialysis on plasma β-thrombo-globulin levels. Trans Am Soc Artif Intern Organs 1979;25:347-350.
33. Sagripanti A. Cupisti A. Baicchi U. Ferdeghini M. Morelli E, Barsotti G: Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993:63:273-278.
34. Sagripanti A. Cupisti A, Ferdeghini M. Pinori E. Barsotti G: Molecular markers of hemostasis activation in nephrotic syndrome. Nephron 1989:51:25-28.
35. Arends JP, Krediet RT. Boeschoten EW. Van der Lelic J. Vcenhof CH. Von dem Borne AE: Improvement of bleeding time, platelet aggregation and platelet count during CAPD treatment. ProcEur Dial Transplant Assoc 1981:18: 280-283.
36. Livio M. Benigni A. Vigano G. Mecca G. Remuzzi G: Moderate doses of aspirin and risk of bleeding in renal failure, Lancet 1986:i:414-416.
37. Baker PN, Williamson JG, Louden KA: Possible low-dose aspirin-induced gastropathy. Lancet 1992:339:550.
38. Giovannetti S: Effects of Dietary' Therapy on Uremic Symptoms and Complications. Boston. Kluwer Academic Publishers, 1989 pp. 231-235.
39. Barsotti G. Morelli E. Guiducci A. Ciardella F. Giannoni A. Lupetti S. Giovannetti S: Reversal of hyperparathyroidism in severe urémies following very low-protein and low-phosphorus diet. Nephron 1982:31:310-313.
40. Barsotti G, Guiducci A. Ciardella F. Giovannetti S: Effects on renal function of a low nitrogen diet supplemented with essential amino acids and ketoanalogues and of hemodialysis and free protein supply in patients with chronic renal failure. Nephron 1981:27:113-117.
41. Mannucci PM. Remuzzi G. Pusincri F. Lombardi R. Valsecchi C, Mecca G. Zimmerman TS: Dcamino-8-if-argininc vasopressin shortens the bleeding time in uremia. N Engl J Med 1983;308:153-160.
42. Remuzzi G. Livio M, Cavcnaghi AE. Marchesi D, Mecca G, Donati MB, Dc Gaetano G: Unbalanced prostaglandin synthesis and plasma factors in uraemic bleeding. A hypothesis. ThrombRes 1978;13:531-536.
43. Remuzzi G. Cavenaghi AE. Mecca G. et al: Prostacyclin-like activity and bleeding in renal failure. Lancet 1977:ii:1195-1197.
44. Remuzzi G. Perico N, Zoja C. et al: Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. J Clin Invest 1990;86: 1768-1171.
45. Castillo R. Lozano T. Escolar G. et al: Defective platelet adhesion on vessel subendothe-lium in uremic patients. Blood 1986;68:337-342.
46. Zwaginga JJ. Ijsseldijk MJW, Beeser-Visscr N, et al: High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. Blood 1990;75:1498-1508.
47. Salzman EW. Neri LL: Adhesiveness of blood platelets in uremia. Thromb Diath Haemorrh 1966;15:84-92.
48. Sloand EM. Sloand JR. Prodouz K, Klein HG. Yu MW. Harvath L. Fricke W: Reduction of platelet glycoprotein lb in uraemia. Br J Haematol 1991:77:375-381.
49. Gralnick HR. McKeown LP. Williams SB, Shafer BC: Plasma and platelet von Willebrand factor defects in uremia. Am J Med 1988:85: 806-810.
50. Eknoyan G. Brown CH: Biochemical abnormalities of platelets in renal failure: Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dcpcndent adenosine triphosphate. Am J Nephrol 1981:1:17-23.
51. Sebekova K. Raucinova M. Dzurik R: Serotonin metabolism in patients w ith decreased renal function. Nephron 1989;53:229-232.
52. Di Minno G. Martinez J. McKean ML. De La Rosa J. Burke FJ. Murphy S: Platelet dysfunction in uremia. Am J Med 1985:79:552-559.
53. Smith MC. Dunn MJ: Impaired platelets thromboxane production in renal failure. Nephron 1981;29:133-137.
54. Remuzzi G. Benigni A. Dodesini P, Schieppati A. Gotti E. Livio M. Mecca G. Donati MB. Dc Gaetano G: Platelet function in patients on maintenance hemodialysis: Depressed or enhanced? Clin Nephrol 1982:17:60-63.
55. Winter M. Frampton G. Bennett A. Machin SJ: Synthesis of thromboxane Bi in uraemia and effects of dialysis. Thromb Res 1983:30:265-268.
56. Rabiner SF. Hrodek O: Platelet factor 3 in normal subjects and patients with renal failure. J Clin Invest 1968:47:901-912.
57. 2’ in platelets from patients with uremia. Blood 1989:73: 172-176.
58. Vlachoyannis J. Schocppe W: Adenylate cyclase activity and cAMP content of human platelets in uraemia. EurJ Clin Invest 1982; 12: 379-381.
59. Shapiro MD, Kclleher SP: Intranasal deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. Am J Nephrol 1984:4:260-261.
60. Aunsholt NA. Schmidt EB, Stoffersen E: 1-Deamino-8-D-arginine vasopressin lowers protein C activity in urémies. Nephron 1989:53: 6-9.
61. Akpolat T. Ozdemir O. Arik N. et al: Effect of desmopressin (DDAVP) on protein C and protein C inhibitors in uremia. Nephron 1993:64: 232-234.
62. Liu Y, Kosfed R. Marcum S: Treatment of uraemic bleeding with conjugated oestrogen. Lancet 1984:ii:887-890.
63. Livio M, Mannucci PM, Vigano G, et al: Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 1986:315:731-735.
64. Janson PA. JubelirerSJ, Weinstein MJ. Deykin D: Treatment of the bleeding tendency in uremia with cryoprecipitatc. N Engl J Med 1980; 303:1318-1322.
65. Deykin D: Uremic bleeding. Kidney Int 1984; 24:698-705.
66. Di Paolo N. Capotondo L. Rossi P. Gaggiotti E, Pula G, Fanetti G: Bleeding tendency of chronic uremia improved by vascular factor. Nephron 1989:52:268-272.
67. Cardillo-Piccolino F. Ghiglionc D. Ceppa P. Villaggio B. Carli F, Allegri P. Bertagno R, Zin-girian M: Fundus angiography with fluorescein-labelled peptide fraction from bovine factor VIII: Correlation with histologic findings. EurJ Ophthalmol 1992:2:135-143.
68. Charytan C. Purtilo O: Glomerular capillary thrombosis and acute renal failure after epsilon-amino caproic acid therapy. N Engl J Med 1969;280:1102-1104.
69. Fernandez Lucas M. Liano F. Navarro JF, et al: Acute renal failure secondary to antifibrinolytic therapy. Nephron 1995;69:478-479.
70. Caruana RJ. Raja RM. Bush JV, Kramer MS. Goldstein SJ: Heparin-free dialysis: Comparative data and results in high-risk patients. Kidney Int 1987:31:1351-1355.
71. Schwab SJ. Onorato JJ, Sharar LR. Dennis PA: Hemodialysis without anticoagulant. Onc-vear prospective trial in hospitalized patients at risk for bleeding. Am J Med 1987;83:405-410.
72. Zusnan RM. Rubin RH, Cato AE. Coccheto DM. Crow JW. Toekoff-Rubm N: Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic treatment. N Engl J Med 1981:304:934-939.
73. Filimberti E, Cinotti S. Salvadori M. Amato M. Longo G. Nazzari M. Morfini M: Hemodialysis with defibrotide: Effects on coagulation parameters. Int J Artif Organs 1990:15:590-594.
74. Kramer P. Broyer M. Brunner FP. Brynger H, Donckerwolcke RA, Jacobs C. Sel wood NH. Wing AJ: Combined report on regular dialysis and transplantation in Europe. Proc Eur Dial Transplant Assoc 1982;4:12-19.
75. Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trials of anti-platelet therapy. II. Maintenance of vascular grafi or arterial patency by antiplatclct therapy. Br Med J 1994:308:159-168.
76. Norman PE. House AK: Heparin reduces intimai hyperplasia seen in microvascular vein graft. Aust NZ J Surg 1991:61:942-948.
77. Mangiarotti G. Canavese C. Thea A. Scgoloni GP. Stratta P. Salomone M. Vcrcellone A: Urokinase treatment for arteriovenous fistu-lae in dialyzed patients. Nephron 1984:36: 60-64.
78. Ahmed A. Shapiro WB. Porush JG: The use of tissue plasminogen activator to declot arteriovenous accesses in hemodialysis patients. Am J Kidney Dis 1993:21:38-43.
79. Roberts AC. Valji K. Bookstcin JJ. Hvc RJ: Pulse-spray pharmacomechanical thrombolysis for treatment of thrombosed dialysis access grafts. Am J Surg 1993:166:221-225.
80. Paulsen D. Rcisether A. Aascn M, Fauchald P: Use of tissue plasminogen activator for reopening of clotted dialysis catheters. Nephron 1993;64:468-470.
81. Vaziri ND. Shah GM. Winer RL. Gonzales E. Patel B. Alikhani S, Nguyen QX, Yamamoto J: Coagulation cascade, fibrinolytic system, antithrombin III. protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis. Thromb Res 1989:53: 173-180.
82. Barton HC. Vaziri ND: Central retinal vein occlusion associated with hemodialysis. Am J MedSci 1979;277:39-47.
83. Port FK. Hccking E. Fiegel P: Priapism during regular hemodialysis. Lancet 1974:30: 1787-1788.
84. Maruyama H. Gejyo F. Hanano M. Arakawa M: Acquired type protein C deficiency in a long-term hemodialysis patient. Nephron 1994:66:348-350.
85. Mehta R. Scott G. Sloand JA. Francis CW: Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med 1990:88:252-257.
86. Soundararajan R. Leehey DJ. Yu AW, Ing TS. Miller JB: Skin necrosis and protein C deficiency associated with vitamin K depletion in a patient with renal failure. Am J Med 1992;93:467-470.
87. Wincarls CG, Pippard MJ, Downing MR. Oliver DO. Reid C. Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;ii:1175-1177.
88. Casati S. Passerini P. Campisc MR. Graziani G. Casana B. Perisic M. Ponticelli C: Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having hemodialysis. Br Med J 1987:295:1017-1020.
89. Burton HR. Walls J: Selection-adjusted comparison oflifc expectancy of patients on continuous ambulatory peritoneal dialysis, haemodialysis. and renal transplantation. Lancet 1987; i;1115-1118.
90. Ibcls LS. Stewart JH. Mahony JF. Neal FC. Sheil AGR: Occlusive arterial disease in uraemic and haemodialysis patients and renal transplant recipients. Q J Med 1977:182:197-214.
91. Kanncl WB: Fibrinogen; A major cardiovascular risk factor; in Ernst E. Koenig W. Low GDO. Meade TW (eds): Fibrinogen: A ‘New’ Cardiovascular Risk Factor. Wien. Blackwell-MZV, 1992, pp 101-109.
92. Murai AT. Miyahara N, Fujimoto M. Matusda M. Kameyama M; Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986;62:249-257.
93. Cressman MD. Heyka RJ. Paganini EH. O'Neil J, Skibiniski CL Hoff HF: Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992:86:475-482.
94. Webb AT. Rcaveley DA. O'Donnel M. O'Connor B. Seed M. Brown EA: Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993;8:609-613.
95. Feldman HH. Held PJ. Hutchinson JT. Stoibcr E. Hartigan MF. Berlin JA: Hemodialysis vascular access morbidity in the United States. Kidney Int 1993:43:1091-1096.
96. Chazan AJ. London MR. Pono ML: Long-term survival of vascular accesses in a large chronic hemodialysis population. Nephron 1998;69: 228-233.
97. Flammel FS. Johnson GC. Collins GM: A critical appraisal of the changing approaches to vascular access for chronic dialysis. Proc Eur Dial Transplant Assoc 1982:19:325-330.
98. Goldwasser P. Avram JT. Collier JT. Michel MA. Gusik SA. Mittman N: Correlates of vascular access occlusion in hemodialysis. Am J Kidney Dis 1994:24:785-794.
99. Diskin CJ. Stokes TJ. Pcnnel TP: Pharmacologic intervention to prevent hemodialysis vascular access thrombosis. Nephron 1993:64:1-26.
100. Hanter HR. Burch J W, Majerus PW, et al: Prevention of thrombosis in patients on haemodialysis by low-dose aspirin. N Engl J Med 1979: 301:577-579.
101. Domoto DR. Bauman JE, Joist JH: Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. Thromb Res 1991:62:737-740.
102. Kobayashi K. Maeda K. Koshikawa S. Kawaguchi Y. et al: Antithrombotic therapy with ticlopidine in chronic renal failure patients on chronic maintenance hemodialysis-A multi-center collaborative double-blind study. Thromb Res 1980:20:255-261.
103. Radmilovic A, Boric Z, Naumovic T. Stamen-kovic M. Musikic P: Shunt thrombosis prevention in hemodialysis patients-double-blind, randomized study: Pentoxifylline vs. placebo. Angiology 1987;38:499-506.
104. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality oflifc and exercise capacity of patient receiving haemodialysis. Br Med J 1990:300:573-578.
105. MacDougall IC. Davies ME, Hallett I. Coch-lin DL. Hutton RD. Coles GA. Williams JD: Coagulation studies and fistula blood flow during erythropoietin and therapy in haemodialysis patients. Nephrol Dial Transplant 1991;6:862-867.
106. Taylor JE. McLaren M. Henderson IS, Belch JJF, Stewart WK: Prothrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant 1992;7:235-239.
107. Tomura S, Nakamura Y. Tachibana K, Degu-chi F. Ando R. Chida Y, Marumo F: Enhanced coagulation and fibrinolysis during treatment with recombinant human erythropoietin in patients undergoing chronic he-modialyis. Blood Purif 1993; 11:370-377.
108. Vaziri ND. Gonzales ED. Wang J. Said S: Bicod coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: Effect of hemodialysis. Am J Kidney Dis 1994:23: 828-835.
109. Warrcll R. Hultin MB, Coller BS: Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med 1979;66:226-228.
110. Kario K, Matsuo T. Matsuo M. Koide M. Yamada T. Nakamura S. Sakata T. Kato H, Miyata T: Marked increase of activated factor VII in uremic patients. Thromb Haemost 1995;73:763-767.
111. Kario K. Matsuo T. Yamada T. Nakao K. Shimano C. Matsuo M: Factor VII hyperactivity in chronic dialysis patients. Thromb Res 1992:67:105-113.
112. Kario K. Matsuo T, Yamada T. Matsuo M: Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 1994:71:275-279.
113. Tomura S. Nakamura Y, Deguchi F, Ando R. Chida Y. Marumo F: Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Thromb Res 1991:64:81-90.
114. Sorensen PJ. Knudsen F. Nielsen AH. Dver-berg J: Protein C assays in uremia. Thromb Res 1989:54:301-310.
115. Faioni EM. Franchi F. Krachmalnicoff A. Valsecchi C, Vigano GL. Remuzzi G, Man-nucci PM: Low levels of the anticoagulant activity of protein C in patients with chronic renal insufficiency: An inhibitor of protein C is present in uremic plasma. Thromb Haemost 1991:66:420-425.
116. Lai K. Yin JA. Yuen PMP. Li PKT: Effect of hemodialysis on protein C, protein S and antithrombin levels. Am. J Kidney Dis 1991; 17:38-42.
117. Weinstein MJ. Chute LE, Schmitt GW. Hamburger RH, Bauer KA, Troll JH. Janson P. Deykin D: Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation. J Clin Invest 1985:76:1406-1411.
118. Edward N: Fibrinolysis in patients on regular hemodialysis. Clin Nephrol 1973:1:97-100.
119. Canavcse S. Slratta P. Pacitti A, Mangiarotti G. Racca M, Oncglio R. Vcrcellone A: Impaired fibrinolysis in uremia: Partial and variable correction by four different dialysis regimens. Clin Nephrol 1982:17:82-89.
120. Winter M. Needham J, Mackic I. Cameron JS: Impaired vessel wall response to venous occlusion in patients with chronic renal failure on maintenance hemodialysis. Clin Nephrol 1984:22:307-313.
121. Brommcr EJP. Barrett-Bergshoeff MM. Allen AR. Schicht I. Bcrtina MR. Schalekamp H: The use of desmopressin acetate (DDA V P) as a test of the fibrinolytic capacity of patients -Analysis of responders and non-responders. Thromb Haemost 1982;48:156-161.
122. Nakamura Y. Tomura S. Tachibana K. Chida Y. Marumo F: Enhanced fibrinolytic activity during the course of hemodialysis. Clin Nephrol 1992:38:90-96.
123. Rabiner SF: The effect of dialysis on platelet function of patients with renal failure: Ann NY Acad Sci 1972;201:234-242.
124. Levin R. Kwaan CH. Ivanovich P: Changes in platelet function during hemodialysis. J Lab Clin Med 1978:92:779-786.
125. Knudsen F. Dycrberg J: Platelets and antithrombin III in uraemia: The acute effect of haemodialysis. Scand J Clin Lab Invest 1985: 45:341-347.
126. Sultan Y. London GM. Goldfarb B. Toulon P. Marchais S.I: Activation of platelets, coagulation and fibrinolysis in patients on longterm haemodialysis: Influence of Cuprophan and polyacrylonitrile membranes. Nephrol Dial Transplant 1990;5:362-378.
127. Tomura S. Nakamura Y. Dcguchi F, Chida Y, Ohno Y. Kodama S. Hayashi T, Suzuki K. Marumo F: Plasma von Willcbrand factor and thrombomodulin as markers of vascular disorders in patients undergoing regular hemodialysis therapy. Thromb Res 1990:58: 413-419.
128. Takagi M. Wada H. Mukai K. Kihira H, Yano S, Minamikawa K. Wakita Y, Nakase T, Nagaya S. Dcguchi K: Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance haemodialysis. Blood Coagul Fibrinolysis 1994:5: 713-717.
129. Arik N. Ozdemir O. Akpolat T. et at: Protein C and its inhibitors during hemodialysis (letter). Nephron 1992;60:488.
130. Reber G, Stoermann C. de Mocrloose P. Rue-din P. Leski M: Hemostatic disturbances by two hollow-fiber hemodialysis membranes. Int J Artif Organs 1992:15:269-275.
131. Kurtz H. Lemcr RG. Weseley S, Nelson JC: Changes in fibrinolytic activity during the course of a single hemodialysis session. Clin Nephrol 1985:24:1-4.
132. Speiscr W, Wojta J. Kominger C. Kirchheimer C, Zazgomik J. Binder BR: Enhanced fibrinolysis caused by tissue plasminogen activator release in hentodialvsis. Kidney Int 1987: 32:280-283.
133. IIS Uni KN. Yin JA. Li PK. Yuen PM. Lui SF: Effect of subcutaneous administration of recombinant human erythropoietin on plasma protein C. protein S. and antithrombin III levels in patients on continuous ambulatory peritoneal dialysis. Int J Artif Organs 1992: 15:264-268.
134. Cavagna R. Schiavon R. Tessarin C. Papa N, Scorrano D. Casol D. De Silvcstro L: Risk factors of ischemic cardiac disease in patients on continuousambulatory peritoneal dialysis. Peril Dial Int 1993; 13(suppl 2):S402-S405.
135. Bauer KA. Rosenberg RD: The pathophysiology of the prcthrombotic stale in humans: Insights gained from studies using markers of hemostatic system activation. Blood 1987:70: 343-350.
136. Pelzer H. Schwarz A. Stübcr W: Determination of human prothrombin activation fragment 1 + 2 in plasma w ith an antibody against a synthetic peptide. Thromb Hacmost 1991; 65:153-159.
137. Bruhn H. Conard J, Mannucci M. Monteagu-do J. Pelzer H. Reverter JC, Samama M. Tri-podi A. Wagner C: Multicentric evaluation of a new assay for prothrombin fragment FI + 2 determination. Thromb Hacmost 1992:68: 413-417.
138. Nosscl HL. Ti M. Kaplan KL. Spanondis K. Soland T, Butler VP Jr: The generation of ftbrinopeptide A in clinical blood samples. Evidence for thrombin activity. J Clin Invest 1976:58:1136-1144.
139. Pelzer H, Schwarz A. Heimburger N: Determination of human thrombin-antithrombin 111 complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988:59:101-106.
140. Ryiatt DB. Blake AS. Cottis LE. et al: An immunoassay for human D-dinter using monoclonal antibodies. Thromb Res 1983: 31:767-778.
141. Sagripanti A. C'ozza V. Camici M. Cupisti A. Baicchi U. Barsotti G: Prothrombin conversion into thrombin is accelerated in patients with chronic uremia. 32nd Congress of the European Renal Association, European Dialysis and Transplant Association. Athens. June 11-14 1995, abstracts, p 143.
142. Ireland HA, Boisclair MD. Lane DA, Thompson E, Curtis JR: Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation. Clin Nephrol 1991:35:26-34.
143. Wilhclmsson S. Asaba H. Gunnarsson B. Kudryk B. Robinson D. Bergstrom J: Measurement of ftbrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis. Clin Nephrol 1981:15:252-258.
144. Lane DA. Ireland H. Knight I. Wolff S. Kyle P. Curtis JR: The significance of fibrinogen dérivâtes in plasma in human renal failure. Br J Haematol 1984:56:251-260.
145. Nakamura Y. Chida Y. Tomura S: Enhanced coagulation-fibrinolysis in patients on regular hcmodialvsis treatment. Nephron 1991:58: 201.
146. Salvini P. Maddaloni E. Levi della Vida MV. Parma A. Corpetti MG. Di Lorenzo M: Epar-ina e lipoproteina (a). Osservazioni in corso di emodialisi. Rccenti Prog Med 1993:84: 828-833.
147. Herbelin A. Anh TN. Zingraff I. Urena P. Descamps-Lascha B: Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int 1990; 37:116-125.
148. Cotran RS. Pober JS: Cytokine-endothelial interaction in inflammation, immunity and vascular injury. J Am Soc Nephrol 1990:1: 225-235.
149. DeCatcrina R. Gintbrone MA Jr: Leukocyte-endothelial interactions and the pathogenesis of atherosclerosis; in Kristiensen SD, Schmidt EB, De Caterina R. Endres S (eds): n-3 Fatty Acids: Prevention and Treatment in Vascular Disease. London. Springer. 1995. pp 10-23.
150. Smith EB. Thompson WD: Fibrin as a factor in atherogenesis. Thromb Res 1994:73:1-19.
151. Bar-Shavit R, Benezra M. Eldor A. et al: Thrombin immobilised to extracellular matrix is a potent mitogen for vascular smooth muscle cells: Nonenzvmatic mode of action. Cell Regul 1990:1:453-463.
152. Fuster V. Bowie EJW, Lewis JC, et al: Resistance to arteriosclerosis in pigs with von Wil-lebrand's disease. Spontaneous and high cholesterol diet-induced arteriosclerosis. J Clin Invest 1978:61:722-729.
153. Bagdade JD: Chronic renal failure and ath-erogcncsis. Scrum factors stimulate the proliferation of human arterial smooth muscle cells. Atherosclerosis 1979:34:243-248.
154. Ross R: The pathogenesis of atherosclerosis: A prospective for the 1990s. Nature 1993; 362:801-809.
155. Strutz F, Muller GA: On the progression of chronic renal disease. Nephron 1995:69:371-379.
156. −Collaboration: Collaboration overview of randomised trials of antiplatelet therapy. I. Prevention of death myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994:308:81-106.
157. Becker R. Ansell J: Antithrombotic therapy. An abbreviated reference for clinicians. Arch Intern Med 1995:155:149-161.
158. Gent M. Easton JD. Hachinski VC, et al: The Canadian American Ticlopidine Study in thromboembolic stroke. Lancet 1989:i: 1215-1220.
159. Hass WK, Easton JD, Adams HP. et al: A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989:321:501-507.
160. ASPECT Research Group: Effect of longterm oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994:343:499-503.
161. Bedani PL. Perini L. Farinelli R. Fabbian F. Fiocchi O, Guerra S, Vanini A. Gilli P: Favorable clinical effects of iloprost infusion in 4 uremic patients with critical limb ischemia. Angiology 1992:43:408-411.
162. Armstrong VW, Schuff-Wemer P. Eisenhauer T. Helmhold M. Stix M. Seidel D: Heparin extracorporeal LDL precipitation: An effective aphercsis procedure for lowering Lp(a) levels. Chcm Phys Lipids 1994:67:315-321.
163. Haas A. Walzl M. Faulborn J. Walzl B. Bcrgloff J. Eckhardt M: Heparin-induzicrte extrakorporale LDL-Präzipitation. Eine neue Therapiemöglichkeit bei Gefässverschlüssen der Netzhaut. Ophthalmologe 1994:91:283-287.
164. Singer DE: Randomized trials of warfarin for atrial fibrillation. N Engl J Med 1992:327: 1451-1453.
165. Neri Scrneri GG. Gensini GF. Carnovali M. Rovclli F. Pirelli S. Fortini A: Effectiveness of low-dose heparin in prevention of myocardial rcinfarction. Lancet 1987;ii:937-942.
166. Goldstein H, Murphy D. Sokol A. et al: Gastric secretion in patients undergoing chronic dialysis. Arch Intern Med 1967:120:645-653.
167. Shepard AM. Stewart WK, Thjodlcifsson B. et al: Further studies of gastric secretion in chronic renal failure. Br Med J 1974:i:96-98.
168. Muto S. Asano Y. Ilosada S. et al: Hypochlor-hydria and hvpogastrinemia and their mutual association with gastrointestinal bleeding in undialyzed and hemodialyzed patients. Nephron 1988;50:10-13.
169. Hirsh J: Heparin. N Engl J Med 1991:324: 1565-1574.
170. Raschkc RA. Reilly BM, Guidtry JR. et al: A weight-based heparin dosing nomogram compared with a 'standard care' nomogram. Ann Intern Med 1993:1 19:874-881.
171. Hull R. Dclmore T. Carter C. et al: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982:306:189-194.
172. Monreal M. Lafoz E. Olive A. et al: Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin®) in patients with venous thromboembolism and contraindications to coumarin. Thrornb Haemost 1994;71:7-11.